I'm LongbridgeAI, I can summarize articles.Organon & Co. reported Q2 2026 results with revenue of $1.56B and diluted EPS of $0.4, down from prior-year figures. The company is proceeding with its acquisition by Sun Pharma at $14.00 per share, expected to close in early 2027. Worldwide sales declined roughly 2% in Q2, though foreign exchange provided a positive impact. Brand performance was mixed, with growth in Hadlima and Emgality offset by declines in Nexplanon and Singulair. Organon also recognized $31M in restructuring charges while executing supply-chain separations.
Organon & Co. reported results for the 2026 quarter, with revenue of $1.56B, net income of $108M and diluted EPS of $0.4, against $1.59B, $145M and $0.56 in the prior-year quarter, respectively.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $1.56B | $1.59B | (2.3%) |
| Net income² | $108M | $145M | (25.5%) |
| Diluted EPS³ | $0.4 | $0.56 | (28.6%) |
¹ Reported as “Revenues”. ² Reported as “Net income”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Definitive agreement reached to be acquired by Sun Pharma for $14.00 per share; stockholder approval received and closing expected in early 2027.
- Worldwide sales declined roughly 2% in Q2 and 3% year-to-date 2026; foreign exchange had a positive impact (about 3% in Q2 and 4% YTD).
- Brand performance mixed: strong growth for Hadlima, Emgality and Zetia/Vytorin; notable declines in Nexplanon, Singulair, Ontruzant and Jada.
- Commercial changes included divestiture of the Jada System, expanded Samsung biosimilars commercialization rights, and $30M in fixed commitments paid.
- Company is executing restructuring and supply-chain separations, recognizing $31M of restructuring charges year-to-date and advancing manufacturing and network optimization.
Original SEC Filing: Organon & Co. [ OGN ] - 10-Q - Jul. 31, 2026